RxSight (RXST) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $35.3M, up 59% year-over-year, driven by strong demand for Light Adjustable Lenses (LAL) and Light Delivery Devices (LDD), with installed base reaching 888 LDDs and over 165,000 LALs implanted since inception.

• LAL procedure volume grew 80% and LDD unit sales rose 18% compared to Q3 2023, expanding the installed base by 51%.

• Gross margin improved to 71.4% in Q3 2024 from 61.9% a year ago, reflecting favorable product mix and cost efficiencies.

• Net loss narrowed to $6.3M ($0.16/share) from $12.4M ($0.35/share) in Q3 2023; adjusted net earnings were $214K.

• Company continues to invest in sales, marketing, and R&D to drive further adoption and product enhancements.

Financial highlights

• Q3 2024 sales: $35.3M (+59% YoY); gross profit: $25.2M (71.4% margin); net loss: $6.3M; adjusted net earnings: $214K.

• Sold 24,554 LALs (up 80% YoY), generating $24.2M; sold 78 LDDs (up 18% YoY), generating $10.1M; LAL revenue comprised 69% of total revenue.

• Operating expenses increased 31% to $34.4M, supporting sales growth and LDD base expansion.

• SG&A expenses: $25.6M, up 34% YoY; R&D expenses: $8.8M, up 24.5% YoY.

• Cash, cash equivalents, and short-term investments totaled $237.1M at quarter-end.

Outlook and guidance

• Raised full-year 2024 revenue guidance to $139M–$140M, implying ~57% YoY growth.

• Gross margin guidance increased to 70–71% (from 68–70%) due to favorable product mix and lower manufacturing costs.

• Full-year operating expenses expected at the low end of $135M–$136M, up 30–31% YoY.

• Management expects continued net operating losses in the near term as investments in growth persist.

• Current cash resources projected to fund operations for at least the next 12 months; no immediate need for additional capital anticipated.